The 10-second takeaway
For the quarter ended March 31 (Q1), Warner Chilcott beat expectations on revenues and crushed expectations on earnings per share.
Compared with the prior-year quarter, revenue dropped and GAAP earnings per share increased.
Margins increased across the board.
Warner Chilcott chalked up revenue of $685.0 million. The 17 analysts polled by S&P Capital IQ expected sales of $646.8 million on the same basis. GAAP reported sales were 9.5% lower than the prior-year quarter's $756.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.16. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.93 per share. GAAP EPS were $0.45 for Q1 versus -$0.10 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 89.5%, 210 basis points better than the prior-year quarter. Operating margin was 38.0%, 770 basis points better than the prior-year quarter. Net margin was 16.5%, 1,970 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $631.5 million. On the bottom line, the average EPS estimate is $0.90.
Next year's average estimate for revenue is $2.53 billion. The average EPS estimate is $3.66.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 147 members out of 175 rating the stock outperform, and 28 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give Warner Chilcott a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Warner Chilcott is outperform, with an average price target of $23.39.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Warner Chilcott the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Warner Chilcott to My Watchlist.
More from The Motley Fool
Actavis Acquisition of Warner Chilcott Clears Final Hurdle
The Irish High Court's approval was the last roadblock to closing the $8.5 billion pharma deal.
The 5 Biggest Risk Factors for Osteoporosis
Osteoporosis and low bone mass affects more than 40 million people in the United States. Here are the five biggest risk factors as for osteoporosis and what biopharmaceutical companies are doing to lower your risk of developing the disease.
Proxy Firms Back Actavis Deal to Acquire Warner Chilcott
Leading up to a special shareholder meeting scheduled for Sept. 10, three advisory firms recommend approval of the proposed $8.5 billion deal.